Targeted therapies in non-small cell lung cancer: Proven concepts and unfulfilled promises

Current Cancer Drug Targets

Volumn 6, Issue 4, 2006, Pages 271-294

  Auberger, Jutta ^a   Loeffler Ragg, Judith ^a   Wurzer, Walter ^a   Hilbe, Wolfgang ^a,b  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Lung cancer; Targeted therapies

Indexed keywords

6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANGIOSTATIN; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BIBX 1382; CANERTINIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; ENDOSTATIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FUMAGILLOL CHLOROACETYLCARBAMATE; GEFITINIB; GEMCITABINE; ICOSANOID; IRINOTECAN; LAPATINIB; METALLOPROTEINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; NAVELBINE; PACLITAXEL; PANITUMUMAB; PELITINIB; PROTEASOME; THALIDOMIDE; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN INHIBITOR;

ANGIOGENESIS; BRADYCARDIA; BREAST CANCER; CANCER CELL; CARCINOGENESIS; CLINICAL TRIAL; COLORECTAL CANCER; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG EFFICACY; DRY SKIN; EPISTAXIS; FATIGUE; HEAD AND NECK CANCER; HUMAN; HYPERTENSION; HYPOTHYROIDISM; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; MALAISE; NAUSEA; NEUTROPENIA; NONHUMAN; OVARY CANCER; PNEUMONIA; QT PROLONGATION; RASH; REVIEW; SIGNAL TRANSDUCTION; THROMBOEMBOLISM; THROMBOSIS; TUMOR GROWTH; VOMITING;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS; DRUG DELIVERY SYSTEMS; HUMANS; LUNG NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN KINASE INHIBITORS; PYRAZINES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33745482368     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800906777441780     Document Type: Review

References (251)

1. Melamed, M. R.; Flehinger, B. J.; Zaman, M. B.; Heelan, R. T.; Perchick, W. A.; Martini, N. Screening for early lung cancer. Results of the Memorial Sloan-Kettering study in New York. Chest 1984, 86, 44-53.
2. Fontana, R. S.; Sanderson, D. R.; Woolner, L. B.; Taylor, W. F.; Miller, W. E.; Muhm, J. R. Lung cancer screening: the Mayo program. J. Occup. Med. 1986, 28, 746-750.
3. Gorlova, O. Y.; Kimmel, M.; Henschke, C. Modeling of long-term screening for lung carcinoma. Cancer 2001, 92, 1531-1540.
4. Schiller, J. H.; Harrington, D.; Belani, C. P.; Langer, C.; Sandler, A.; Krook, J.; Zhu, J.; Johnson, D. H. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. 2002, 346, 92-98.
5. Greenlee, R. T.; Hill-Harmon, M. B.; Murray, T.; Thun, M. Cancer statistics, 2001. CA Cancer J. Clin. 2001, 51, 15-36.
6. Giaccone, G. State of the art in systemic treatment of lung cancer. Eur. J. Cancer 2001, 37(Suppl. 7), S99-S114.
7. Mountain, C. F. A new international staging system for lung cancer. Chest 1986, 89, 225S-233S.
8. Hirsch, F. R.; Franklin, W. A.; Gazdar, A. F.; Bunn, P. A., Jr. Early detection of lung cancer: clinical perspectives of recent advances in biology and radiology. Clin. Cancer Res. 2001, 7, 5-22.
9. Hilbe, W.; Dirnhofer, S.; Greil, R.; Woll, E. Biomarkers in non-small cell lung cancer prevention. Eur. J. Cancer Prev. 2004, 13, 425-436.
10. Fong, K. M.; Sekido, Y.; Gazdar, A. F.; Minna, J. D. Lung cancer. 9: Molecular biology of lung cancer: clinical implications. Thorax 2003, 58, 892-900.
11. Franklin, W. A.; Veve, R.; Hirsch, F. R.; Helfrich, B. A.; Bunn, P. A., Jr. Epidermal growth factor receptor family in lung cancer and premalignancy. Semin. Oncol. 2002, 29, 3-14.
12. Jacobson, D. R. In Lung Tumors: Fundamental Biology and Clinical Management: ras mutations in lung cancer; Brambilla, C. and Brambilla, E.; Marcel Decker: New York, 1999, pp. 139-156.
13. Kwiatkowski, D. J.; Harpole, D. H., Jr.; Godleski, J.; Herndon, J. E.; Shieh, D. B.; Richards, W.; Blanco, R.; Xu, H. J.; Strauss, G. M.; Sugarbaker, D. J. Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: clinical implications. J. Clin. Oncol. 1998, 16, 2468-2477.
14. Lemon, S. J.; Sabichi, A. L.; Birrer, M. J. In Cellular Cancer Markers: Genetic alterations in lung cancer; Garret, C. T. and Sell, S.; Humana Press: Totowa, 1995, pp. 209-230.
15. Hilbe, W.; Dirnhofer, S.; Oberwasserlechner, F.; Eisterer, W.; Ammann, K.; Schmid, T.; Hilbe, G.; Thaler, J.; Woll, E. Immunohistochemical typing of non-small cell lung cancer on cryostat sections: correlation with clinical parameters and prognosis. J. Clin. Pathol. 2003, 56, 736-741.
16. Yi, E. S.; Harclerode, D.; Gondo, M.; Stephenson, M.; Brown, R. W.; Younes, M.; Cagle, P. T. High c-erbB-3 protein expression is associated with shorter survival in advanced non-small cell lung carcinomas. Mod. Pathol. 1997, 10, 142-148.
17. Kris, M.; Azzoli, C. G.; Miller, V. A. In ASCO Educational Book: Epidermal growth factor receptor blockade: Targeted therapy for non-small-cell lung cancer. 2002, pp. 693-699.
18. Rosell, R. Toward customized trastuzumab in HER-2/neu-overexpressing non-small-cell lung cancers. J. Clin. Oncol. 2004, 22, 1171-1173.
19. Kris, M. G.; Natale, R. B.; Herbst, R. S.; Lynch, T. J., Jr.; Prager, D.; Belani, C. P.; Schiller, J. H.; Kelly, K.; Spiridonidis, H.; Sandler, A.; Albain, K. S.; Cella, D.; Wolf, M. K.; Averbuch, S. D.; Ochs, J. J.; Kay, A. C. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003, 290, 2149-2158.
20. Fukuoka, M.; Yano, S.; Giaccone, G.; Tamura, T.; Nakagawa, K.; Douillard, J. Y.; Nishiwaki, Y.; Vansteenkiste, J.; Kudoh, S.; Rischin, D.; Eek, R.; Horai, T.; Noda, K.; Takata, I.; Smit, E.; Averbuch, S.; Macleod, A.; Feyereislova, A.; Dong, R. P.; Baselga, J. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J. Clin. Oncol. 2003, 21, 2237-2246.
21. Wakeling, A. E.; Guy, S. P.; Woodburn, J. R.; Ashton, S. E.; Curry, B. J.; Barker, A. J.; Gibson, K. H. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res. 2002, 62, 5749-5754.
22. Lynch, T. J.; Bell, D. W.; Sordella, R.; Gurubhagavatula, S.; Okimoto, R. A.; Brannigan, B. W.; Harris, P. L.; Haserlat, S. M.; Supko, J. G.; Haluska, F. G.; Louis, D. N.; Christiani, D. C.; Settleman, J.; Haber, D. A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004, 350, 2129-2139.
23. Paez, J. G.; Janne, P. A.; Lee, J. C.; Tracy, S.; Greulich, H.; Gabriel, S.; Herman, P.; Kaye, F. J.; Lindeman, N.; Boggon, T. J.; Naoki, K.; Sasaki, H.; Fujii, Y.; Eck, M. J.; Sellers, W. R.; Johnson, B. E.; Meyerson, M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304, 1497-1500.
24. Herbst, R. S.; Maddox, A. M.; Rothenberg, M. L.; Small, E. J.; Rubin, E. H.; Baselga, J.; Rojo, F.; Hong, W. K.; Swaisland, H.; Averbuch, S. D.; Ochs, J.; LoRusso, P. M. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J. Clin. Oncol. 2002, 20, 3815-3825.
25. Ranson, M.; Hammond, L. A.; Ferry, D.; Kris, M.; Tullo, A.; Murray, P. I.; Miller, V.; Averbuch, S.; Ochs, J.; Morris, C.; Feyereislova, A.; Swaisland, H.; Rowinsky, E. K. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J. Clin. Oncol. 2002, 20, 2240-2250.
26. Miller, V. A.; Johnson, D. H.; Krug, L. M.; Pizzo, B.; Tyson, L.; Perez, W.; Krozely, P.; Sandler, A.; Carbone, D.; Heelan, R. T.; Kris, M. G.; Smith, R.; Ochs, J. Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer. J. Clin. Oncol. 2003, 21, 2094-2100.
27. Pfister, D. G.; Johnson, D. H.; Azzoli, C. G.; Sause, W.; Smith, T. J.; Baker S Jr; Olak, J.; Stover, D.; Strawn, J. R.; Turrisi, A. T.; Somerfield, M. R. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J. Clin. Oncol. 2004, 22, 330-353.
28. Kim, K. S.; Jeong, J. Y.; Kim, Y. C.; Na, K. J.; Kim, Y. H.; Ahn, S. J.; Baek, S. M.; Park, C. S.; Park, C. M.; Kim, Y. I.; Lim, S. C.; Park, K. O. Predictors of the response to gefitinib in refractory non-small cell lung cancer. Clin. Cancer Res. 2005, 11, 2244-2251.
29. Kobayashi, S.; Boggon, T. J.; Dayaram, T.; Janne, P. A.; Kocher, O.; Meyerson, M.; Johnson, B. E.; Eck, M. J.; Tenen, D. G.; Halmos, B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2005, 352, 786-792.
30. Herbst, R. S.; Giaccone, G.; Schiller, J. H.; Natale, R. B.; Miller, V.; Manegold, C.; Scagliotti, G.; Rosell, R.; Oliff, I.; Reeves, J. A.; Wolf, M. K.; Krebs, A. D.; Averbuch, S. D.; Ochs, J. S.; Grous, J.; Fandi, A.; Johnson, D. H. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. J. Clin. Oncol. 2004, 22, 785-794.
31. Giaccone, G.; Herbst, R. S.; Manegold, C.; Scagliotti, G.; Rosell, R.; Miller, V.; Natale, R. B.; Schiller, J. H.; von Pawel, J.; Pluzanska, A.; Gatzemeier, U.; Grous, J.; Ochs, J. S.; Averbuch, S. D.; Wolf, M. K.; Rennie, P.; Fandi, A.; Johnson, D. H. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1. J. Clin. Oncol. 2004, 22, 777-784.
32. Johnson, D. H. Targeted therapy in non-small cell lung cancer: myth or reality. Lung Cancer 2003, 41(Suppl. 1), S3-S8.
33. Herbst, R. S. Erlotinib (Tarceva): an update on the clinical trial program. Semin. Oncol. 2003, 30, 34-46.
34. Hidalgo, M.; Bloedow, D. Pharmacokinetics and pharmacodynamics: maximizing the clinical potential of Erlotinib (Tarceva). Semin. Oncol. 2003, 30, 25-33.
35. Perez-Soler, R. Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer. Clin. Lung Cancer 2004, 6(Suppl. 1), S20-S23.
36. Perez-Soler, R.; Chachoua, A.; Hammond, L. A.; Rowinsky, E. K.; Huberman, M.; Karp, D.; Rigas, J.; Clark, G. M.; Santabarbara, P.; Bonomi, P. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J. Clin. Oncol. 2004, 22, 3238-3247.
37. Patel, J. D.; Miller, V. A.; Kris, M. G.; et.al. Encouraging activity and durable responses demonstrated by the EGFR tyrosine kinase inhibitor erlotinib (Tarceva TM, OSI-774) in patients with advanced bronchioalveolar (BAC) cell carcinoma. Lung Cancer 2003, 41, S56.
38. Perez-Soler, R.; Chachoua, A.; Hammond, L. A.; Rowinsky, E. K.; Huberman, M.; Karp, D.; Rigas, J.; Clark, G. M.; Santabarbara, P.; Bonomi, P. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J. Clin. Oncol. 2004, 22, 3238-3247.
39. Fuster, L. M.; Sandler, A. B. Select clinical trials of erlotinib (OSI-774) in non-small-cell lung cancer with emphasis on phase III outcomes. Clin. Lung Cancer 2004, 6(Suppl. 1), S24-S29.
40. Herbst, R. S.; Johnson, D. H.; Mininberg, E.; Carbone, D. P.; Henderson, T.; Kim, E. S.; Blumenschein, G., Jr.; Lee, J. J.; Liu, D. D.; Truong, M. T.; Hong, W. K.; Tran, H.; Tsao, A.; Xie, D.; Ramies, D. A.; Mass, R.; Seshagiri, S.; Eberhard, D. A.; Kelley, S. K.; Sandler, A. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J. Clin. Oncol. 2005, 23, 2544-2555.
41. Wood, E. R.; Truesdale, A. T.; McDonald, O. B.; Yuan, D.; Hassell, A.; Dickerson, S. H.; Ellis, B.; Pennisi, C.; Horne, E.; Lackey, K.; Alligood, K. J.; Rusnak, D. W.; Gilmer, T. M.; Shewchuk, L. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res. 2004, 64, 6652-6659.
42. Rusnak, D. W.; Affleck, K.; Cockerill, S. G.; Stubberfield, C.; Harris, R.; Page, M.; Smith, K. J.; Guntrip, S. B.; Carter, M. C.; Shaw, R. J.; Jowett, A.; Stables, J.; Topley, P.; Wood, E. R.; Brignola, P. S.; Kadwell, S. H.; Reep, B. R.; Mullin, R. J.; Alligood, K. J.; Keith, B. R.; Crosby, R. M.; Murray, D. M.; Knight, W. B.; Gilmer, T. M.; Lackey, K. The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. Cancer Res. 2001, 61, 7196-7203.
43. Xia, W.; Mullin, R. J.; Keith, B. R.; Liu, L. H.; Ma, H.; Rusnak, D. W.; Owens, G.; Alligood, K. J.; Spector, N. L. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 2002, 21, 6255-6263.
44. Burris, H. A. III; Hurwitz, H. I.; Dees, E. C.; Dowlati, A.; Blackwell, K. L.; O'Neil, B.; Marcom, P. K.; Ellis, M. J.; Overmoyer, B.; Jones, S. F.; Harris, J. L.; Smith, D. A.; Koch, K. M.; Stead, A.; Mangum, S.; Spector, N. L. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J. Clin. Oncol. 2005, 23, 5305-5313.
45. Spector, N. L.; Xia, W.; Burris, H., III; Hurwitz, H.; Dees, E. C.; Dowlati, A.; O'Neil, B.; Overmoyer, B.; Marcom, P. K.; Blackwell, K. L.; Smith, D. A.; Koch, K. M.; Stead, A.; Mangum, S.; Ellis, M. J.; Liu, L.; Man, A. K.; Bremer, T. M.; Harris, J.; Bacus, S. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J. Clin. Oncol. 2005, 23, 2502-2512.
46. Burris, H. A., III Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. Oncologist 2004, 9(Suppl. 3), 10-15.
47. Gridelli, C.; Rossi, A.; Maione, P. Treatment of non-small-cell lung cancer: state of the art and development of new biologic agents. Oncogene 2003, 22, 6629-6638.
48. Slichenmyer, W. J.; Elliott, W. L.; Fry, D. W. CI-1033, a pan-erbB tyrosine kinase inhibitor. Semin. Oncol. 2001, 28, 80-85.
49. Calvo, E.; Tolcher, A. W.; Hammond, L. A.; Patnaik, A.; de Bono, J. S.; Eiseman, I. A.; Olson, S. C.; Lenehan, P. F.; McCreery, H.; Lorusso, P.; Rowinsky, E. K. Administration of CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule: a phase I pharmacokinetic and food effect study. Clin. Cancer Res. 2004, 10, 7112-7120.
50. Peng, D.; Fan, Z.; Lu, Y.; DeBlasio, T.; Scher, H.; Mendelsohn, J. Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145. Cancer Res. 1996, 56, 3666-3669.
51. Ciardiello, F.; Bianco, R.; Damiano, V.; De Lorenzo, S.; Pepe, S.; De Placido, S.; Fan, Z.; Mendelsohn, J.; Bianco, A. R.; Tortora, G. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin. Cancer Res. 1999, 5, 909-916.
52. Shin, D. M.; Donato, N. J.; Perez-Soler, R.; Shin, H. J.; Wu, J. Y.; Zhang, P.; Lawhorn, K.; Khuri, F. R.; Glisson, B. S.; Myers, J.; Clayman, G.; Pfister, D.; Falcey, J.; Waksal, H.; Mendelsohn, J.; Hong, W. K. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin. Cancer Res. 2001, 7, 1204-1213.
53. Cunningham, D.; Humblet, Y.; Siena, S.; Khayat, D.; Bleiberg, H.; Santoro, A.; Bets, D.; Mueser, M.; Harstrick, A.; Verslype, C.; Chau, I.; Van Cutsem, E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 2004, 351, 337-345.
54. Baselga, J.; Pfister, D.; Cooper, M. R.; Cohen, R.; Burtness, B.; Bos, M.; D'Andrea, G.; Seidman, A.; Norton, L.; Gunnett, K.; Falcey, J.; Anderson, V.; Waksal, H.; Mendelsohn, J. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J. Clin. Oncol. 2000, 18, 904-914.
55. Yang, X. D.; Jia, X. C.; Corvalan, J. R.; Wang, P.; Davis, C. G. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit. Rev. Oncol. Hematol. 2001, 38, 17-23.
56. Baselga, J.; Tripathy, D.; Mendelsohn, J.; Baughman, S.; Benz, C. C.; Dantis, L.; Sklarin, N. T.; Seidman, A. D.; Hudis, C. A.; Moore, J.; Rosen, P. P.; Twaddell, T.; Henderson, I. C.; Norton, L. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J. Clin. Oncol. 1996, 14, 737-744.
57. Esteva, F. J.; Valero, V.; Booser, D.; Guerra, L. T.; Murray, J. L.; Pusztai, L.; Cristofanilli, M.; Arun, B.; Esmaeli, B.; Fritsche, H. A.; Sneige, N.; Smith, T. L.; Hortobagyi, G. N. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J. Clin. Oncol. 2002, 20, 1800-1808.
58. Langer, C. J.; Stephenson, P.; Thor, A.; Vangel, M.; Johnson, D. H. Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598. J. Clin. Oncol. 2004, 22, 1180-1187.
59. Johnson, D. H.; Fehrenbacher, L.; Novotny, W. F.; Herbst, R. S.; Nemunaitis, J. J.; Jablons, D. M.; Langer, C. J.; DeVore, R. F., III; Gaudreault, J.; Damico, L. A.; Holmgren, E.; Kabbinavar, F. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol. 2004, 22, 2184-2191.
60. Tan, D.; Deeb, G.; Wang, J.; Slocum, H. K.; Winston, J.; Wiseman, S.; Beck, A.; Sait, S.; Anderson, T.; Nwogu, C.; Ramnath, N.; Loewen, G. HER-2/neu protein expression and gene alteration in stage I-IIIA non-small-cell lung cancer: a study of 140 cases using a combination of high throughput tissue microarray, immunohistochemistry, and fluorescent in situ hybridization. Diagn. Mol. Pathol. 2003, 12, 201-211.
61. Gatzemeier, U.; Groth, G.; Butts, C.; van Zandwijk, N.; Shepherd, F.; Ardizzoni, A.; Barton, C.; Ghahramani, P.; Hirsh, V. Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann. Oncol. 2004, 15, 19-27.
62. Meert, A. P.; Martin, B.; Paesmans, M.; Berghmans, T.; Mascaux, C.; Verdebout, J. M.; Delmotte, P.; Lafitte, J. J.; Sculier, J. P. The role of HER-2/neu expression on the survival of patients with lung cancer: a systematic review of the literature. Br. J. Cancer 2003, 89, 959-965.
63. Zinner, R. G.; Glisson, B. S.; Fossella, F. V.; Pisters, K. M.; Kies, M. S.; Lee, P. M.; Massarelli, E.; Sabloff, B.; Fritsche, H. A., Jr.; Ro, J. Y.; Ordonez, N. G.; Tran, H. T.; Yang, Y.; Smith, T. L.; Mass, R. D.; Herbst, R. S. Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease. Lung Cancer 2004, 44, 99-110.
64. Willett, C. G.; Boucher, Y.; di Tomaso, E.; Duda, D. G.; Munn, L. L.; Tong, R. T.; Chung, D. C.; Sahani, D. V.; Kalva, S. P.; Kozin, S. V.; Mino, M.; Cohen, K. S.; Scadden, D. T.; Hartford, A. C.; Fischman, A. J.; Clark, J. W.; Ryan, D. P.; Zhu, A. X.; Blaszkowsky, L. S.; Chen, H. X.; Shellito, P. C.; Lauwers, G. Y.; Jain, R. K. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med. 2004, 10, 145-147.
65. Brambilla, C.; Brambilla, E. In Lung Tumors-fundametal biology and clinical management: Angiogenesis in lung cancer; Brambilla, C.; Brambilla, E., Eds.; Marcel Dekker Inc.: 1999, pp. 383.
66. Hart, I. R.; Saini, A. Biology of tumour metastasis. Lancet 1992, 339, 1453-1457.
67. Liekens, S.; De Clercq, E.; Neyts, J. Angiogenesis: regulators and clinical applications. Biochem. Pharmacol. 2001, 61, 253-270.
68. Ferrara, N. Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int. 1999, 56, 794-814.
69. Asahara, T.; Takahashi, T.; Masuda, H.; Kalka, C.; Chen, D.; Iwaguro, H.; Inai, Y.; Silver, M.; Isner, J. M. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J. 1999, 18, 3964-3972.
70. Lyden, D.; Hattori, K.; Dias, S.; Costa, C.; Blaikie, P.; Butros, L.; Chadburn, A.; Heissig, B.; Marks, W.; Witte, L.; Wu, Y.; Hicklin, D.; Zhu, Z.; Hackett, N. R.; Crystal, R. G.; Moore, M. A.; Hajjar, K. A.; Manova, K.; Benezra, R.; Rafii, S. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med. 2001, 7, 1194-1201.
71. Li, C. Y.; Shan, S.; Huang, Q.; Braun, R. D.; Lanzen, J.; Hu, K.; Lin, P.; Dewhirst, M. W. Initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers in rodent models. J. Natl. Cancer Inst. 2000, 92, 143-147.
72. O'Byrne, K. J.; Koukourakis, M. I.; Giatromanolaki, A.; Cox, G.; Turley, H.; Steward, W. P.; Gatter, K.; Harris, A. L. Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. Br. J. Cancer 2000, 82, 1427-1432.
73. Harpole, D. H., Jr.; Richards, W. G.; Herndon, J. E.; Sugarbaker, D. J. Angiogenesis and molecular biologic substaging in patients with stage I non-small cell lung cancer. Ann. Thorac. Surg. 1996, 61, 1470-1476.
74. Baillie, R.; Carlile, J.; Pendleton, N.; Schor, A. M. Prognostic value of vascularity and vascular endothelial growth factor expression in non-small cell lung cancer. J. Clin. Pathol. 2001, 54, 116-120.
75. Han, H.; Silverman, J. F.; Santucci, T. S.; Macherey, R. S.; d'Amato, T. A.; Tung, M. Y.; Weyant, R. J.; Landreneau, R. J. Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis. Ann. Surg. Oncol. 2001, 8, 72-79.
76. Yuan, A.; Yu, C. J.; Kuo, S. H.; Chen, W. J.; Lin, F. Y.; Luh, K. T.; Yang, P. C.; Lee, Y. C. Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer. J. Clin. Oncol. 2001, 19, 432-441.
77. Ohta, Y.; Nozaki, Z.; Nozawa, H.; Kamesui, T.; Tsunezuka, Y.; Oda, M.; Watanabe, G. The predictive value of vascular endothelial growth factor and nm23 for the diagnosis of occult metastasis in non-small cell lung cancer. Jpn. J. Cancer Res. 2001, 92, 361-366.
78. Fontanini, G.; Lucchi, M.; Vignati, S.; Mussi, A.; Ciardiello, F.; De Laurentiis, M.; De Placido, S.; Basolo, F.; Angeletti, C. A.; Bevilacqua, G. Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study. J. Natl. Cancer Inst. 1997, 89, 881-886.
79. Shepherd, F. A.; Sridhar, S. S. Angiogenesis inhibitors under study for the treatment of lung cancer. Lung Cancer 2003, 41(Suppl. 1), S63-S72.
80. Miller, K. D.; Chap, L. I.; Holmes, F. A.; Cobleigh, M. A.; Marcom, P. K.; Fehrenbacher, L.; Dickler, M.; Overmoyer, B. A.; Reimann, J. D.; Sing, A. P.; Langmuir, V.; Rugo, H. S. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J. Clin. Oncol. 2005, 23, 792-799.
81. Sledge, G. W., Jr.; Miller, K. D. Angiogenesis and antiangiogenic therapy. Curr. Probl. Cancer 2002, 26, 1-60.
82. Yang, J. C.; Haworth, L.; Sherry, R. M.; Hwu, P.; Schwartzentruber, D. J.; Topalian, S. L.; Steinberg, S. M.; Chen, H. X.; Rosenberg, S. A. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 2003, 349, 427-434.
83. Hurwitz, H.; Fehrenbacher, L.; Novotny, W.; Cartwright, T.; Hainsworth, J.; Heim, W.; Berlin, J.; Baron, A.; Griffing, S.; Holmgren, E.; Ferrara, N.; Fyfe, G.; Rogers, B.; Ross, R.; Kabbinavar, F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2004, 350, 2335-2342.
84. Harmey, J. H.; Bouchier-Hayes, D. Vascular endothelial growth factor (VEGF), a survival factor for tumour cells: implications for anti-angiogenic therapy. Bioessays 2002, 24, 280-283.
85. Lee, C. G.; Heijn, M.; di Tomaso, E.; Griffon-Etienne, G.; Ancukiewicz, M.; Koike, C.; Park, K. R.; Ferrara, N.; Jain, R. K.; Suit, H. D.; Boucher, Y. Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res. 2000, 60, 5565-5570.
86. Sweeney, C. J.; Miller, K. D.; Sissons, S. E.; Nozaki, S.; Heilman, D. K.; Shen, J.; Sledge, G. W., Jr. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res. 2001, 61, 3369-3372.
87. Herbst, R. S.; Johnson, D. H.; Mininberg, E.; Carbone, D. P.; Henderson, T.; Kim, E. S.; Blumenschein, G., Jr.; Lee, J. J.; Liu, D. D.; Truong, M. T.; Hong, W. K.; Tran, H.; Tsao, A.; Xie, D.; Ramies, D. A.; Mass, R.; Seshagiri, S.; Eberhard, D. A.; Kelley, S. K.; Sandler, A. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J. Clin. Oncol. 2005, 23, 2544-2555.
88. Herbst, R. S.; Sandler, A. B. Non-small cell lung cancer and antiangiogenic therapy: what can be expected of bevacizumab? Oncologist. 2004, 9(Suppl. 1), 19-26.
89. Sandler, A. B.; Johnson, D. H.; Herbst, R. S. Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer. Clin. Cancer Res. 2004, 10, 4258s-4262s.
90. Holash, J.; Davis, S.; Papadopoulos, N.; Croll, S. D.; Ho, L.; Russell, M.; Boland, P.; Leidich, R.; Hylton, D.; Burova, E.; Ioffe, E.; Huang, T.; Radziejewski, C.; Bailey, K.; Fandl, J. P.; Daly, T.; Wiegand, S. J.; Yancopoulos, G. D.; Rudge, J. S. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc. Natl. Acad. Sci. USA 2002, 99, 11393-11398.
91. Kim, E. S.; Serur, A.; Huang, J.; Manley, C. A.; McCrudden, K. W.; Frischer, J. S.; Soffer, S. Z.; Ring, L.; New, T.; Zabski, S.; Rudge, J. S.; Holash, J.; Yancopoulos, G. D.; Kandel, J. J.; Yamashiro, D. J. Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc. Natl. Acad. Sci. USA 2002, 99, 11399-11404.
92. Huang, J.; Frischer, J. S.; Serur, A.; Kadenhe, A.; Yokoi, A.; McCrudden, K. W.; New, T.; O'Toole, K.; Zabski, S.; Rudge, J. S.; Holash, J.; Yancopoulos, G. D.; Yamashiro, D. J.; Kandel, J. J. Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc. Natl. Acad. Sci. USA 2003, 100, 7785-7790.
93. D'Amato, R. J.; Loughnan, M. S.; Flynn, E.; Folkman, J. Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. USA 1994, 91, 4082-4085.
94. Singhal, S.; Mehta, J.; Desikan, R.; Ayers, D.; Roberson, P.; Eddlemon, P.; Munshi, N.; Anaissie, E.; Wilson, C.; Dhodapkar, M.; Zeddis, J.; Barlogie, B. Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. 1999, 341, 1565-1571.
95. Barlogie, B.; Desikan, R.; Eddlemon, P.; Spencer, T.; Zeldis, J.; Munshi, N.; Badros, A.; Zangari, M.; Anaissie, E.; Epstein, J.; Shaughnessy, J.; Ayers, D.; Spoon, D.; Tricot, G. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001, 98, 492-494.
96. Kisker, O.; Onizuka, S.; Banyard, J.; Komiyama, T.; Becker, C. M.; Achilles, E. G.; Barnes, C. M.; O'Reilly, M. S.; Folkman, J.; Pirie-Shepherd, S. R. Generation of multiple angiogenesis inhibitors by human pancreatic cancer. Cancer Res. 2001, 61, 7298-7304.
97. O'Reilly, M. S.; Boehm, T.; Shing, Y.; Fukai, N.; Vasios, G.; Lane, W. S.; Flynn, E.; Birkhead, J. R.; Olsen, B. R.; Folkman, J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997, 88, 277-285.
98. O'Reilly, M. S. The preclinical evaluation of angiogenesis inhibitors. Invest. New Drugs 1997, 15, 5-13.
99. O'Reilly, M. S.; Holmgren, L.; Shing, Y.; Chen, C.; Rosenthal, R. A.; Moses, M.; Lane, W. S.; Cao, Y.; Sage, E. H.; Folkman, J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994, 79, 315-328.
100. Prox, D.; Becker, C.; Pirie-Shepherd, S. R.; Celik, I.; Folkman, J.; Kisker, O. Treatment of human pancreatic cancer in mice with angiogenic inhibitors. World J. Surg. 2003, 27, 405-411.
101. Zhang, G. F.; Wang, Y. H.; Zhang, M. A.; Wang, Q.; Luo, Y. B.; Wang, D. S.; Han, C. R. [Inhibition of growth and metastases of human colon cancer xenograft in nude mice by angiogenesis inhibitor endostatin]. Ai. Zheng 2002, 21, 50-53.
102. Katzenstein, H. M.; Salwen, H. R.; Nguyen, N. N.; Meitar, D.; Cohn, S. L. Antiangiogenic therapy inhibits human neuroblastoma growth. Med. Pediatr. Oncol. 2001, 36, 190-193.
103. Beecken, W. D.; Fernandez, A.; Joussen, A. M.; Achilles, E. G.; Flynn, E.; Lo, K. M.; Gillies, S. D.; Javaherian, K.; Folkman, J.; Shing, Y. Effect of antiangiogenic therapy on slowly growing, poorly vascularized tumors in mice. J. Natl. Cancer Inst. 2001, 93, 382-387.
104. Herbst, R. S.; Hess, K. R.; Tran, H. T.; Tseng, J. E.; Mullani, N. A.; Charnsangavej, C.; Madden, T.; Davis, D. W.; McConkey, D. J.; O'Reilly, M. S.; Ellis, L. M.; Pluda, J.; Hong, W. K.; Abbruzzese, J. L. Phase I study of recombinant human endostatin in patients with advanced solid tumors. J. Clin. Oncol. 2002, 20, 3792-3803.
105. Eder, J. P., Jr.; Supko, J. G.; Clark, J. W.; Puchalski, T. A.; Garcia-Carbonero, R.; Ryan, D. P.; Shulman, L. N.; Proper, J.; Kirvan, M.; Rattner, B.; Connors, S.; Keogan, M. T.; Janicek, M. J.; Fogler, W. E.; Schnipper, L.; Kinchla, N.; Sidor, C.; Phillips, E.; Folkman, J.; Kufe, D. W. Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J. Clin. Oncol. 2002, 20, 3772-3784.
106. Beerepoot, L. V.; Witteveen, E. O.; Groenewegen, G.; Fogler, W. E.; Sim, B. K.; Sidor, C.; Zonnenberg, B. A.; Schramel, F.; Gebbink, M. F.; Voest, E. E. Recombinant human angiostatin by twice-daily subcutaneous injection in advanced cancer: a pharmacokinetic and long-term safety study. Clin. Cancer Res. 2003, 9, 4025-4033.
107. Ingber, D.; Fujita, T.; Kishimoto, S.; Sudo, K.; Kanamaru, T.; Brem, H.; Folkman, J. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 1990, 348, 555-557.
108. Herbst, R. S.; Takeuchi, H.; Teicher, B. A. Paclitaxel/carboplatin administration along with antiangiogenic therapy in non-small-cell lung and breast carcinoma models. Cancer Chemother. Pharmacol. 1998, 41, 497-504.
109. Herbst, R. S.; Madden, T. L.; Tran, H. T.; Blumenschein, G. R., Jr.; Meyers, C. A.; Seabrooke, L. F.; Khuri, F. R.; Puduvalli, V. K.; Allgood, V.; Fritsche, H. A., Jr.; Hinton, L.; Newman, R. A.; Crane, E. A.; Fossella, F. V.; Dordal, M.; Goodin, T.; Hong, W. K. Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer. J. Clin. Oncol. 2002, 20, 4440-4447.
110. Tran, H. T.; Blumenschein, G. R., Jr.; Lu, C.; Meyers, C. A.; Papadimitrakopoulou, V.; Fossella, F. V.; Zinner, R.; Madden, T.; Smythe, L. G.; Puduvalli, V. K.; Munden, R.; Truong, M.; Herbst, R. S. Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors. Cancer Chemother. Pharmacol. 2004, 54, 308-314.
111. Hurwitz, H.; Fehrenbacher, L.; Novotny, W.; Cartwright, T.; Hainsworth, J.; Heim, W.; Berlin, J.; Baron, A.; Griffing, S.; Holmgren, E.; Ferrara, N.; Fyfe, G.; Rogers, B.; Ross, R.; Kabbinavar, F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2004, 350, 2335-2342.
112. Heymach, J. V. ZD6474 - clinical experience to date. Br. J. Cancer 2005, 92(Suppl. 1), S14-S20.
113. Dannenberg, A. J.; Altorki, N. K.; Boyle, J. O.; Dang, C.; Howe, L. R.; Weksler, B. B.; Subbaramaiah, K. Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol. 2001, 2, 544-551.
114. Ramalingam, S.; Belani, C. P. Cyclooxygenase-2 inhibitors in lung cancer. Clin. Lung Cancer 2004, 5, 245-253.
115. Koki, A.; Khan, N. K.; Woerner, B. M.; Dannenberg, A. J.; Olson, L.; Seibert, K.; Edwards, D.; Hardy, M.; Isakson, P.; Masferrer, J. L. Cyclooxygenase-2 in human pathological disease. Adv. Exp. Med. Biol. 2002, 507, 177-184.
116. Lin, M. T.; Lee, R. C.; Yang, P. C.; Ho, F. M.; Kuo, M. L. Cyclooxygenase-2 inducing Mcl-1-dependent survival mechanism in human lung adenocarcinoma CL1.0 cells. Involvement of phosphatidylinositol 3-kinase/Akt pathway. J. Biol. Chem. 2001, 276, 48997-49002.
117. Dohadwala, M.; Batra, R. K.; Luo, J.; Lin, Y.; Krysan, K.; Pold, M.; Sharma, S.; Dubinett, S. M. Autocrine/paracrine prostaglandin E2 production by non-small cell lung cancer cells regulates matrix metalloproteinase-2 and CD44 in cyclooxygenase-2-dependent invasion. J. Biol. Chem. 2002, 277, 50828-50833.
118. Sharma, S.; Stolina, M.; Yang, S. C.; Baratelli, F.; Lin, J. F.; Atianzar, K.; Luo, J.; Zhu, L.; Lin, Y.; Huang, M.; Dohadwala, M.; Batra, R. K.; Dubinett, S. M. Tumor cyclooxygenase 2-dependent suppression of dendritic cell function. Clin. Cancer Res. 2003, 9, 961-968.
119. Leahy, K. M.; Koki, A. T.; Masferrer, J. L. Role of cyclooxygenases in angiogenesis. Curr. Med. Chem. 2000, 7, 1163-1170.
120. Brown, J. R.; DuBois, R. N. Cyclooxygenase as a target in lung cancer. Clin. Cancer Res. 2004, 10, 4266s-4269s.
121. Hida, T.; Yatabe, Y.; Achiwa, H.; Muramatsu, H.; Kozaki, K.; Nakamura, S.; Ogawa, M.; Mitsudomi, T.; Sugiura, T.; Takahashi, T. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res. 1998, 58, 3761-3764.
122. Hosomi, Y.; Yokose, T.; Hirose, Y.; Nakajima, R.; Nagai, K.; Nishiwaki, Y.; Ochiai, A. Increased cyclooxygenase 2 (COX-2) expression occurs frequently in precursor lesions of human adenocarcinoma of the lung. Lung Cancer 2000, 30, 73-81.
123. Anderson, W. F.; Umar, A.; Viner, J. L.; Hawk, E. T. The role of cyclooxygenase inhibitors in cancer prevention. Curr. Pharm. Des 2002, 8, 1035-1062.
124. Wolff, H.; Saukkonen, K.; Anttila, S.; Karjalainen, A.; Vainio, H.; Ristimaki, A. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res. 1998, 58, 4997-5001.
125. Huang, M.; Stolina, M.; Sharma, S.; Mao, J. T.; Zhu, L.; Miller, P. W.; Wollman, J.; Herschman, H.; Dubinett, S. M. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res. 1998, 58, 1208-1216.
126. Fang, H. Y.; Lin, T. S.; Lin, J. P.; Wu, Y. C.; Chow, K. C.; Wang, L. S. Cyclooxygenase-2 in human non-small cell lung cancer. Eur. J. Surg. Oncol. 2003, 29, 171-177.
127. Khuri, F. R.; Wu, H.; Lee, J. J.; Kemp, B. L.; Lotan, R.; Lippman, S. M.; Feng, L.; Hong, W. K.; Xu, X. C. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin. Cancer Res. 2001, 7, 861-867.
128. Brabender, J.; Park, J.; Metzger, R.; Schneider, P. M.; Lord, R. V.; Holscher, A. H.; Danenberg, K. D.; Danenberg, P. V. Prognostic significance of cyclooxygenase 2 mRNA expression in non-small cell lung cancer. Ann. Surg. 2002, 235, 440-443.
129. Achiwa, H.; Yatabe, Y.; Hida, T.; Kuroishi, T.; Kozaki, K.; Nakamura, S.; Ogawa, M.; Sugiura, T.; Mitsudomi, T.; Takahashi, T. Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin. Cancer Res. 1999, 1001.
130. Kim, H. S.; Youm, H. R.; Lee, J. S.; Min, K. W.; Chung, J. H.; Park, C. S. Correlation between cyclooxygenase-2 and tumor angiogenesis in non-small cell lung cancer. Lung Cancer 2003, 42, 163-170.
131. Lu, C.; Soria, J. C.; Tang, X.; Xu, X. C.; Wang, L.; Mao, L.; Lotan, R.; Kemp, B.; Bekele, B. N.; Feng, L.; Hong, W. K.; Khuri, F. R. Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers. J. Clin. Oncol. 2004, 22, 4575-4583.
132. Koki, A. T.; Leahy, K. M.; Masferrer, J. L. Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy. Exp. Opin. Investig. Drugs 1999, 8, 1623-1638.
133. Milas, L. Cyclooxygenase-2 (COX-2) enzyme inhibitors as potential enhancers of tumor radioresponse. Semin. Radiat. Oncol. 2001, 11, 290-299.
134. Furuta, Y.; Hunter, N.; Barkley, T., Jr.; Hall, E.; Milas, L. Increase in radioresponse of murine tumors by treatment with indomethacin. Cancer Res. 1988, 48, 3008-3013.
135. Milas, L.; Hanson, W. R. Eicosanoids and radiation. Eur. J. Cancer 1995, 31A, 1580-1585.
136. Altorki, N. K.; Keresztes, R. S.; Port, J. L.; Libby, D. M.; Korst, R. J.; Flieder, D. B.; Ferrara, C. A.; Yankelevitz, D. F.; Subbaramaiah, K.; Pasmantier, M. W.; Dannenberg, A. J. Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. J. Clin. Oncol. 2003, 21, 2645-2650.
137. Solomon, S. D.; McMurray, J. J.; Pfeffer, M. A.; Wittes, J.; Fowler, R.; Finn, P.; Anderson, W. F.; Zauber, A.; Hawk, E.; Bertagnolli, M. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N. Engl. J. Med. 2005, 352, 1071-1080.
138. Nussmeier, N. A.; Whelton, A. A.; Brown, M. T.; Langford, R. M.; Hoeft, A.; Parlow, J. L.; Boyce, S. W.; Verburg, K. M. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N. Engl. J. Med. 2005, 352, 1081-1091.
139. Hidalgo, M.; Eckhardt, S. G. Development of matrix metalloproteinase inhibitors in cancer therapy. J. Natl. Cancer Inst. 2001, 93, 178-193.
140. Sato, H.; Seiki, M. Membrane-type matrix metalloproteinases (MT-MMPs) in tumor metastasis. J. Biochem. (Tokyo) 1996, 119, 209-215.
141. Nelson, A. R.; Fingleton, B.; Rothenberg, M. L.; Matrisian, L. M. Matrix metalloproteinases: biologic activity and clinical implications. J. Clin. Oncol. 2000, 18, 1135-1149.
142. Liotta, L. A.; Steeg, P. S.; Stetler-Stevenson, W. G. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991, 64, 327-336.
143. Passlick, B.; Sienel, W.; Seen-Hibler, R.; Wockel, W.; Thetter, O.; Mutschler, W.; Pantel, K. Overexpression of matrix metalloproteinase 2 predicts unfavorable outcome in early-stage non-small cell lung cancer. Clin. Cancer Res. 2000, 6, 3944-3948.
144. Sienel, W.; Hellers, J.; Morresi-Hauf, A.; Lichtinghagen, R.; Mutschler, W.; Jochum, M.; Klein, C.; Passlick, B.; Pantel, K. Prognostic impact of matrix metalloproteinase-9 in operable non-small cell lung cancer. Int. J. Cancer 2003, 103, 647-651.
145. Aljada, I. S.; Ramnath, N.; Donohue, K.; Harvey, S.; Brooks, J. J.; Wiseman, S. M.; Khoury, T.; Loewen, G.; Slocum, H. K.; Anderson, T. M.; Bepler, G.; Tan, D. Upregulation of the tissue inhibitor of metalloproteinase-1 protein is associated with progression of human non-small-cell lung cancer. J. Clin. Oncol. 2004, 22, 3218-3229.
146. Gill, J. H.; Kirwan, I. G.; Seargent, J. M.; Martin, S. W.; Tijani, S.; Anikin, V. A.; Mearns, A. J.; Bibby, M. C.; Anthoney, A.; Loadman, P. M. MMP-10 is overexpressed, proteolytically active, and a potential target for therapeutic intervention in human lung carcinomas. Neoplasia. 2004, 6, 777-785.
147. Cho, N. H.; Hong, K. P.; Hong, S. H.; Kang, S.; Chung, K. Y.; Cho, S. H. MMP expression profiling in recurred stage IB lung cancer. Oncogene 2004, 23, 845-851.
148. Hofmann, H. S.; Hansen, G.; Richter, G.; Taege, C.; Simm, A.; Silber, R. E.; Burdach, S. Matrix metalloproteinase-12 expression correlates with local recurrence and metastatic disease in non-small cell lung cancer patients. Clin. Cancer Res. 2005, 11, 1086-1092.
149. Denis, L. J.; Verweij, J. Matrix metalloproteinase inhibitors: present achievements and future prospects. Invest. New Drugs 1997, 15, 175-185.
150. Wojtowicz-Praga, S.; Torri, J.; Johnson, M.; Steen, V.; Marshall, J.; Ness, E.; Dickson, R.; Sale, M.; Rasmussen, H. S.; Chiodo, T. A.; Hawkins, M. J. Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. J. Clin. Oncol. 1998, 16, 2150-2156.
151. Bissett, D.; O'Byrne, K. J.; von Pawel, J.; Gatzemeier, U.; Price, A.; Nicolson, M.; Mercier, R.; Mazabel, E.; Penning, C.; Zhang, M. H.; Collier, M. A.; Shepherd, F. A. Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer. J. Clin. Oncol. 2005, 23, 842-849.
152. Leighl, N. B.; Paz-Ares, L.; Douillard, J. Y.; Peschel, C.; Arnold, A.; Depierre, A.; Santoro, A.; Betticher, D. C.; Gatzemeier, U.; Jassem, J.; Crawford, J.; Tu, D.; Bezjak, A.; Humphrey, J. S.; Voi, M.; Galbraith, S.; Hann, K.; Seymour, L.; Shepherd, F. A. Randomized Phase III Study of Matrix Metalloproteinase Inhibitor BMS-275291 in Combination With Paclitaxel and Carboplatin in Advanced Non-Small-Cell Lung Cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18. J. Clin. Oncol. 2005, 23, 2831-2839.
153. Douillard, J. Y.; Peschel, C.; Shepherd, F.; Paz-Ares, L.; Arnold, A.; Davis, M.; Tonato, M.; Smylie, M.; Tu, D.; Voi, M.; Humphrey, J.; Ottaway, J.; Young, K.; Vreckem, A. V.; Seymour, L. Randomized phase II feasibility study of combining the matrix metalloproteinase inhibitor BMS-275291 with paclitaxel plus carboplatin in advanced non-small cell lung cancer. Lung Cancer 2004, 46, 361-368.
154. Lin, T. S.; Chiou, S. H.; Wang, L. S.; Huang, H. H.; Chiang, S. F.; Shih, A. Y.; Chen, Y. L.; Chen, C. Y.; Hsu, C. P.; Hsu, N. Y.; Chou, M. C.; Kuo, S. J.; Chow, K. C. Expression spectra of matrix metalloproteinases in metastatic non-small cell lung cancer. Oncol. Rep. 2004, 12, 717-723.
155. Richardson, P. G.; Barlogie, B.; Berenson, J.; Singhal, S.; Jagannath, S.; Irwin, D.; Rajkumar, S. V.; Srkalovic, G.; Alsina, M.; Alexanian, R.; Siegel, D.; Orlowski, R. Z.; Kuter, D.; Limentani, S. A.; Lee, S.; Hideshima, T.; Esseltine, D. L.; Kauffman, M.; Adams, J.; Schenkein, D. P.; Anderson, K. C. A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 2003, 348, 2609-2617.
156. Elliott, P. J.; Zollner, T. M.; Boehncke, W. H. Proteasome inhibition: a new anti-inflammatory strategy. J. Mol. Med. 2003, 81, 235-245.
157. Hochstrasser, M. Protein degradation or regulation: Ub the judge. Cell 1996, 84, 813-815.
158. Adams, J.; Palombella, V. J.; Sausville, E. A.; Johnson, J.; Destree, A.; Lazarus, D. D.; Maas, J.; Pien, C. S.; Prakash, S.; Elliott, P. J. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999, 59, 2615-2622.
159. Kumatori, A.; Tanaka, K.; Inamura, N.; Sone, S.; Ogura, T.; Matsumoto, T.; Tachikawa, T.; Shin, S.; Ichihara, A. Abnormally high expression of proteasomes in human leukemic cells. Proc. Natl. Acad. Sci. USA 1990, 87, 7071-7075.
160. Adams, J. Development of the proteasome inhibitor PS-341. Oncologist 2002, 7, 9-16.
161. Mack, P. C.; Davies, A. M.; Lara, P. N.; Gumerlock, P. H.; Gandara, D. R. Integration of the proteasome inhibitor PS-341 (Velcade) into the therapeutic approach to lung cancer. Lung Cancer 2003, 41(Suppl. 1), S89-S96.
162. Lara, P. N., Jr.; Davies, A. M.; Mack, P. C.; Mortenson, M. M.; Bold, R. J.; Gumerlock, P. H.; Gandara, D. R. Proteasome inhibition with PS-341 (bortezomib) in lung cancer therapy. Semin. Oncol. 2004, 31, 40-46.
163. Tsukamoto, S.; Sugio, K.; Sakada, T.; Ushijima, C.; Yamazaki, K.; Sugimachi, K. Reduced expression of cell-cycle regulator p27(Kip1) correlates with a shortened survival in non-small cell lung cancer. Lung Cancer 2001, 34, 83-90.
164. Shoji, T.; Tanaka, F.; Takata, T.; Yanagihara, K.; Otake, Y.; Hanaoka, N.; Miyahara, R.; Nakagawa, T.; Kawano, Y.; Ishikawa, S.; Katakura, H.; Wada, H. Clinical significance of p21 expression in non-small-cell lung cancer. J. Clin. Oncol. 2002, 20, 3865-3871.
165. An, W. G.; Hwang, S. G.; Trepel, J. B.; Blagosklonny, M. V. Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition. Leukemia 2000, 14, 1276-1283.
166. Luque, I.; Gelinas, C. Rel/NF-kappa B and I kappa B factors in oncogenesis. Semin. Cancer Biol. 1997, 8, 103-111.
167. Bharti, A. C.; Aggarwal, B. B. Nuclear factor-kappa B and cancer: its role in prevention and therapy. Biochem. Pharmacol. 2002, 64, 883-888.
168. Denlinger, C. E.; Rundall, B. K.; Jones, D. R. Modulation of antiapoptotic cell signaling pathways in non-small cell lung cancer: the role of NF-kappaB. Semin. Thorac. Cardiovasc. Surg. 2004, 16, 28-39.
169. Denlinger, C. E.; Rundall, B. K.; Keller, M. D.; Jones, D. R. Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis. Ann. Thorac. Surg. 2004, 78, 1207-1214.
170. Shibata, A.; Nagaya, T.; Imai, T.; Funahashi, H.; Nakao, A.; Seo, H. Inhibition of NF-kappaB activity decreases the VEGF mRNA expression in MDA-MB-231 breast cancer cells. Breast Cancer Res. Treat. 2002, 73, 237-243.
171. Aghajanian, C.; Soignet, S.; Dizon, D. S.; Pien, C. S.; Adams, J.; Elliott, P. J.; Sabbatini, P.; Miller, V.; Hensley, M. L.; Pezzulli, S.; Canales, C.; Daud, A.; Spriggs, D. R. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin. Cancer Res. 2002, 8, 2505-2511.
172. Bunn, P. A., Jr. The potential role of proteasome inhibitors in the treatment of lung cancer. Clin. Cancer Res. 2004, 10, 4263s-4265s.
173. Kaina, B.; Haas, S.; Kappes, H. A general role for c-Fos in cellular protection against DNA-damaging carcinogens and cytostatic drugs. Cancer Res. 1997, 57, 2721-2731.
174. Rodenhuis, S. ras and human tumors. Semin. Cancer Biol. 1992, 3, 241-247.
175. Minamoto, T.; Mai, M.; Ronai, Z. K-ras mutation: early detection in molecular diagnosis and risk assessment of colorectal, pancreas, and lung cancers - a review. Cancer Detect. Prev. 2000, 24, 1-12.
176. Rodenhuis, S.; Slebos, R. J. The ras oncogenes in human lung cancer. Am. Rev. Respir. Dis. 1990, 142, S27-S30.
177. Rodenhuis, S.; Slebos, R. J.; Boot, A. J.; Evers, S. G.; Mooi, W. J.; Wagenaar, S. S.; van Bodegom, P. C.; Bos, J. L. Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. Cancer Res. 1988, 48, 5738-5741.
178. Rodenhuis, S.; van de Wetering, M. L.; Mooi, W. J.; Evers, S. G.; van Zandwijk, N.; Bos, J. L. Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. N. Engl. J. Med. 1987, 317, 929-935.
179. Mitsudomi, T.; Viallet, J.; Mulshine, J. L.; Linnoila, R. I.; Minna, J. D.; Gazdar, A. F. Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines. Oncogene 1991, 6, 1353-1362.
180. Suzuki, Y.; Orita, M.; Shiraishi, M.; Hayashi, K.; Sekiya, T. Detection of ras gene mutations in human lung cancers by single-strand conformation polymorphism analysis of polymerase chain reaction products. Oncogene 1990, 5, 1037-1043.
181. Reichel, M. B.; Ohgaki, H.; Petersen, I.; Kleihues, P. p53 mutations in primary human lung tumors and their metastases. Mol. Carcinog. 1994, 9, 105-109.
182. Greatens, T. M.; Niehans, G. A.; Rubins, J. B.; Jessurun, J.; Kratzke, R. A.; Maddaus, M. A.; Niewoehner, D. E. Do molecular markers predict survival in non-small-cell lung cancer? Am. J. Respir. Crit. Care Med. 1998, 157, 1093-1097.
183. Westra, W. H.; Slebos, R. J.; Offerhaus, G. J.; Goodman, S. N.; Evers, S. G.; Kensler, T. W.; Askin, F. B.; Rodenhuis, S.; Hruban, R. H. K-ras oncogene activation in lung adenocarcinomas from former smokers. Evidence that K-ras mutations are an early and irreversible event in the development of adenocarcinoma of the lung. Cancer 1993, 72, 432-438.
184. Silini, E. M.; Bosi, F.; Pellegata, N. S.; Volpato, G.; Romano, A.; Nazari, S.; Tinelli, C.; Ranzani, G. N.; Solcia, E.; Fiocca, R. K-ras gene mutations: an unfavorable prognostic marker in stage I lung adenocarcinoma. Virchows Arch. 1994, 424, 367-373.
185. Rosell, R.; Monzo, M.; Pifarre, A.; Ariza, A.; Sanchez, J. J.; Moreno, I.; Maurel, J.; Lopez, M. P.; Abad, A.; de Anta, J. M. Molecular staging of non-small cell lung cancer according to Kras genotypes. Clin. Cancer Res. 1996, 2, 1083-1086.
186. Hilbe, W.; Dlaska, M.; Duba, H. C.; Dirnhofer, S.; Eisterer, W.; Oberwasserlechner, F.; Mildner, A.; Schmid, T.; Kuhr, T.; Woll, E. Automated real-time PCR to determine K-ras codon 12 mutations in non-small cell lung cancer: comparison with immunohistochemistry and clinico-pathological features. Int. J. Oncol. 2003, 23, 1121-1126.
187. Schneider, P. M.; Praeuer, H. W.; Stoeltzing, O.; Boehm, J.; Manning, J.; Metzger, R.; Fink, U.; Wegerer, S.; Hoelscher, A. H.; Roth, J. A. Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer. Br. J. Cancer 2000, 83, 473-479.
188. Keohavong, P.; Zhu, D.; Melacrinos, A. C.; DeMichele, M. A.; Weyant, R. J.; Luketich, J. D.; Testa, J. R.; Fedder, M.; Siegfried, J. M. Detection of low-fraction K-ras mutations in primary lung tumors using a sensitive method. Int. J. Cancer 1997, 74, 162-170.
189. Konishi, T.; Huang, C. L.; Adachi, M.; Taki, T.; Inufusa, H.; Kodama, K.; Kohno, N.; Miyake, M. The K-ras gene regulates vascular endothelial growth factor gene expression in non-small cell lung cancers. Int. J. Oncol. 2000, 16, 501-511.
190. Mao, L.; Hruban, R. H.; Boyle, J. O.; Tockman, M.; Sidransky, D. Detection of oncogene mutations in sputum precedes diagnosis of lung cancer. Cancer Res. 1994, 54, 1634-1637.
191. Destro, A.; Bianchi, P.; Alloisio, M.; Laghi, L.; Di Gioia, S.; Malesci, A.; Cariboni, U.; Gribaudi, G.; Bulfamante, G.; Marchetti, A.; Bosari, S.; Infante, M.; Ravasi, G.; Roncalli, M. Kras and p16(INK4A)alterations in sputum of NSCLC patients and in heavy asymptomatic chronic smokers. Lung Cancer 2004, 44, 23-32.
192. Kato, K.; Cox, A. D.; Hisaka, M. M.; Graham, S. M.; Buss, J. E.; Der, C. J. Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. Proc. Natl. Acad. Sci. USA 1992, 89, 6403-6407.
193. Reiss, Y.; Goldstein, J. L.; Seabra, M. C.; Casey, P. J.; Brown, M. S. Inhibition of purified p21ras farnesyl:protein transferase by Cys-AAX tetrapeptides. Cell 1990, 62, 81-88.
194. Kohl, N. E.; Omer, C. A.; Conner, M. W.; Anthony, N. J.; Davide, J. P.; deSolms, S. J.; Giuliani, E. A.; Gomez, R. P.; Graham, S. L.; Hamilton, K. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat. Med. 1995, 1, 792-797.
195. Nielsen, L. L.; Shi, B.; Hajian, G.; Yaremko, B.; Lipari, P.; Ferrari, E.; Gurnani, M.; Malkowski, M.; Chen, J.; Bishop, W. R.; Liu, M. Combination therapy with the farnesyl protein transferase inhibitor SCH66336 and SCH58500 (p53 adenovirus) in preclinical cancer models. Cancer Res. 1999, 59, 5896-5901.
196. Adjei, A. A.; Erlichman, C.; Davis, J. N.; Cutler, D. L.; Sloan, J. A.; Marks, R. S.; Hanson, L. J.; Svingen, P. A.; Atherton, P.; Bishop, W. R.; Kirschmeier, P.; Kaufmann, S. H. A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity. Cancer Res. 2000, 60, 1871-1877.
197. Khuri, F. R.; Glisson, B. S.; Kim, E. S.; Statkevich, P.; Thall, P. F.; Meyers, M. L.; Herbst, R. S.; Munden, R. F.; Tendler, C.; Zhu, Y.; Bangert, S.; Thompson, E.; Lu, C.; Wang, X. M.; Shin, D. M.; Kies, M. S.; Papadimitrakopoulou, V.; Fossella, F. V.; Kirschmeier, P.; Bishop, W. R.; Hong, W. K. Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors. Clin. Cancer Res. 2004, 10, 2968-2976.
198. Adjei, A. A.; Mauer, A.; Bruzek, L.; Marks, R. S.; Hillman, S.; Geyer, S.; Hanson, L. J.; Wright, J. J.; Erlichman, C.; Kaufmann, S. H.; Vokes, E. E. Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 2003, 21, 1760-1766.
199. Tamm, I.; Dorken, B.; Hartmann, G. Antisense therapy in oncology: new hope for an old idea? Lancet 2001, 358, 489-497.
200. Nemunaitis, J.; Holmlund, J. T.; Kraynak, M.; Richards, D.; Bruce, J.; Ognoskie, N.; Kwoh, T. J.; Geary, R.; Dorr, A.; Von Hoff, D.; Eckhardt, S. G. Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer. J. Clin. Oncol. 1999, 17, 3586-3595.
201. Villalona-Calero, M. A.; Ritch, P.; Figueroa, J. A.; Otterson, G. A.; Belt, R.; Dow, E.; George, S.; Leonardo, J.; McCachren, S.; Miller, G. L.; Modiano, M.; Valdivieso, M.; Geary, R.; Oliver, J. W.; Holmlund, J. A phase I/II study of LY900003, an antisense inhibitor of protein kinase C-alpha, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer. Clin. Cancer Res. 2004, 10, 6086-6093.
202. Vansteenkiste, J.; Canon, J. L.; Riska, H.; Pirker, R.; Peterson, P.; John, W.; Mali, P.; Lahn, M. Randomized phase II evaluation of aprinocarsen in combination with gemcitabine and cisplatin for patients with advanced/metastatic non-small cell lung cancer. Invest. New Drugs 2005, 23, 263-269.
203. Hainaut, P.; Hernandez, T.; Robinson, A.; Rodriguez-Tome, P.; Flores, T.; Hollstein, M.; Harris, C. C.; Montesano, R. IARC Database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualisation tools. Nucleic Acids Res. 1998, 26, 205-213.
204. Tammemagi, M. C.; McLaughlin, J. R.; Bull, S. B. Meta-analyses of p53 tumor suppressor gene alterations and clinicopathological features in resected lung cancers. Cancer Epidemiol. Biomarkers Prev. 1999, 8, 625-634.
205. Mitsudomi, T.; Hamajima, N.; Ogawa, M.; Takahashi, T. Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. Clin. Cancer Res. 2000, 6, 4055-4063.
206. Owen-Schaub, L. B.; Zhang, W.; Cusack, J. C.; Angelo, L. S.; Santee, S. M.; Fujiwara, T.; Roth, J. A.; Deisseroth, A. B.; Zhang, W. W.; Kruzel, E.; Wild-type human p53 and a temperaturesensitive mutant induce Fas/APO-1 expression. Mol. Cell Biol. 1995, 15, 3032-3040.
207. Stambolic, V.; MacPherson, D.; Sas, D.; Lin, Y.; Snow, B.; Jang, Y.; Benchimol, S.; Mak, T. W. Regulation of PTEN transcription by p53. Mol. Cell 2001, 8, 317-325.
208. Miyashita, T.; Reed, J. C. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995, 80, 293-299.
209. Nakano, K.; Vousden, K. H. PUMA, a novel proapoptotic gene, is induced by p53. Mol. Cell 2001, 7, 683-694.
210. Yu, J.; Zhang, L.; Hwang, P. M.; Kinzler, K. W.; Vogelstein, B. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol. Cell 2001, 7, 673-682.
211. Vousden, K. H.; Lu, X. Live or let die: the cell's response to p53. Nat. Rev. Cancer 2002, 2, 594-604.
212. Tsujimoto, Y.; Shimizu, S. Bcl-2 family: life-or-death switch. FEBS Lett. 2000, 466, 6-10.
213. Brambilla, E.; Negoescu, A.; Gazzeri, S.; Lantuejoul, S.; Moro, D.; Brambilla, C.; Coll, J. L. Apoptosis-related factors p53, Bcl2, and Bax in neuroendocrine lung tumors. Am. J. Pathol. 1996, 149, 1941-1952.
214. Groeger, A. M.; Esposito, V.; De Luca, A.; Cassandro, R.; Tonini, G.; Ambrogi, V.; Baldi, F.; Goldfarb, R.; Mineo, T. C.; Baldi, A.; Wolner, E. Prognostic value of immunohistochemical expression of p53, bax, Bcl-2 and Bcl-xL in resected non-small-cell lung cancers. Histopathology 2004, 44, 54-63.
215. Borner, M. M.; Brousset, P.; Pfanner-Meyer, B.; Bacchi, M.; Vonlanthen, S.; Hotz, M. A.; Altermatt, H. J.; Schlaifer, D.; Reed, J. C.; Betticher, D. C. Expression of apoptosis regulatory proteins of the Bcl-2 family and p53 in primary resected non-small-cell lung cancer. Br. J. Cancer 1999, 79, 952-958.
216. Wang, L. G.; Liu, X. M.; Kreis, W.; Budman, D. R. The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemother. Pharmacol. 1999, 44, 355-361.
217. Ganansia-Leymarie, V.; Bischoff, P.; Bergerat, J. P.; Holl, V. Signal transduction pathways of taxanes-induced apoptosis. Curr. Med. Chem. Anti. -Canc. Agents 2003, 3, 291-306.
218. Koty, P. P.; Zhang, H.; Levitt, M. L. Antisense bcl-2 treatment increases programmed cell death in non-small cell lung cancer cell lines. Lung Cancer 1999, 23, 115-127.
219. Zangemeister-Wittke, U.; Leech, S. H.; Olie, R. A.; Simoes-Wust, A. P.; Gautschi, O.; Luedke, G. H.; Natt, F.; Haner, R.; Martin, P.; Hall, J.; Nalin, C. M.; Stahel, R. A. A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells. Clin. Cancer Res. 2000, 6, 2547-2555.
220. Herbst, R. S.; Frankel, S. R. Oblimersen sodium (Genasense bcl-2 antisense oligonucleotide): a rational therapeutic to enhance apoptosis in therapy of lung cancer. Clin. Cancer Res. 2004, 10, 4245s-4248s.
221. Nishizaki, M.; Meyn, R. E.; Levy, L. B.; Atkinson, E. N.; White, R. A.; Roth, J. A.; Ji, L. Synergistic inhibition of human lung cancer cell growth by adenovirus-mediated wild-type p53 gene transfer in combination with docetaxel and radiation therapeutics in vitro and in vivo. Clin. Cancer Res. 2001, 7, 2887-2897.
222. Swisher, S. G.; Roth, J. A.; Nemunaitis, J.; Lawrence, D. D.; Kemp, B. L.; Carrasco, C. H.; Connors, D. G.; El Naggar, A. K.; Fossella, F.; Glisson, B. S.; Hong, W. K.; Khuri, F. R.; Kurie, J. M.; Lee, J. J.; Lee, J. S.; Mack, M.; Merritt, J. A.; Nguyen, D. M.; Nesbitt, J. C.; Perez-Soler, R.; Pisters, K. M.; Putnam, J. B., Jr.; Richli, W. R.; Savin, M.; Waugh, M. K.; Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J. Natl. Cancer Inst. 1999, 91, 763-771.
223. Swisher, S. G.; Roth, J. A.; Komaki, R.; Gu, J.; Lee, J. J.; Hicks, M.; Ro, J. Y.; Hong, W. K.; Merritt, J. A.; Ahrar, K.; Atkinson, N. E.; Correa, A. M.; Dolormente, M.; Dreiling, L.; El Naggar, A. K.; Fossella, F.; Francisco, R.; Glisson, B.; Grammer, S.; Herbst, R.; Huaringa, A.; Kemp, B.; Khuri, F. R.; Kurie, J. M.; Liao, Z.; McDonnell, T. J.; Morice, R.; Morello, F.; Munden, R.; Papadimitrakopoulou, V.; Pisters, K. M.; Putnam, J. B., Jr.; Sarabia, A. J.; Shelton, T.; Stevens, C.; Shin, D. M.; Smythe, W. R.; Vaporciyan, A. A.; Walsh, G. L.; Yin, M. Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin. Cancer Res. 2003, 9, 93-101.
224. Mangelsdorf, D. J.; Evans, R. M. The RXR heterodimers and orphan receptors. Cell 1995, 83, 841-850.
225. Mangelsdorf, D. J.; Ong, E. S.; Dyck, J. A.; Evans, R. M. Nuclear receptor that identifies a novel retinoic acid response pathway. Nature 1990, 345, 224-229.
226. Chambon, P. A decade of molecular biology of retinoic acid receptors. FASEB J. 1996, 10, 940-954.
227. Sporn, M. B.; Roberts, A. B. Role of retinoids in differentiation and carcinogenesis. J. Natl. Cancer Inst. 1984, 73, 1381-1387.
228. Rigas, J. R.; Dragnev, K. H. Emerging role of rexinoids in non-small cell lung cancer: focus on bexarotene. Oncologist 2005, 10, 22-33.
229. Miller, V. A.; Benedetti, F. M.; Rigas, J. R.; Verret, A. L.; Pfister, D. G.; Straus, D.; Kris, M. G.; Crisp, M.; Heyman, R.; Loewen, G. R.; Truglia, J. A.; Warrell, R. P., Jr. Initial clinical trial of a selective retinoid X receptor ligand, LGD1069. J. Clin. Oncol. 1997, 15, 790-795.
230. Khuri, F. R.; Rigas, J. R.; Figlin, R. A.; Gralla, R. J.; Shin, D. M.; Munden, R.; Fox, N.; Huyghe, M. R.; Kean, Y.; Reich, S. D.; Hong, W. K. Multi-institutional phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 2001, 19, 2626-2637.
231. Rizvi, N.; Hawkins, M. J.; Eisenberg, P. D.; Yocum, R. C.; Reich, S. D. Placebo-controlled trial of bexarotene, a retinoid x receptor agonist, as maintenance therapy for patients treated with chemotherapy for advanced non-small-cell lung cancer. Clin. Lung Cancer 2001, 2, 210-215.
232. Tirado, O. M.; Mateo-Lozano, S.; Notario, V. Rapamycin induces apoptosis of JN-DSRCT-1 cells by increasing the Bax : Bcl-xL ratio through concurrent mechanisms dependent and independent of its mTOR inhibitory activity. Oncogene 2005, 24(20), 3348-3357.
233. Vignot, S.; Faivre, S.; Aguirre, D.; Raymond, E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann. Oncol. 2005, 16, 525-537.
234. Zhao, R.; Babani, S.; Gao, F.; Liu, L.; Goldman, I. D. The mechanism of transport of the multitargeted antifolate (MTA) and its cross-resistance pattern in cells with markedly impaired transport of methotrexate. Clin. Cancer Res. 2000, 6, 3687-3695.
235. Goldman, I. D.; Zhao, R. Molecular, biochemical, and cellular pharmacology of pemetrexed. Semin. Oncol. 2002, 29, 3-17.
236. Adjei, A. A. Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent. Clin. Cancer Res. 2004, 10, 4276s-4280s.
237. Rinaldi, D. A.; Burris, H. A.; Dorr, F. A.; Woodworth, J. R.; Kuhn, J. G.; Eckardt, J. R.; Rodriguez, G.; Corso, S. W.; Fields, S. M.; Langley, C.; . Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation. J. Clin. Oncol. 1995, 13, 2842-2850.
238. McDonald, A. C.; Vasey, P. A.; Adams, L.; Walling, J.; Woodworth, J. R.; Abrahams, T.; McCarthy, S.; Bailey, N. P.; Siddiqui, N.; Lind, M. J.; Calvert, A. H.; Twelves, C. J.; Cassidy, J.; Kaye, S. B. A phase I and pharmacokinetic study of LY231514, the multitargeted antifolate. Clin. Cancer Res. 1998, 4, 605-610.
239. Rinaldi, D. A.; Kuhn, J. G.; Burris, H. A.; Dorr, F. A.; Rodriguez, G.; Eckhardt, S. G.; Jones, S.; Woodworth, J. R.; Baker, S.; Langley, C.; Mascorro, D.; Abrahams, T.; Von Hoff, D. D. A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother. Pharmacol. 1999, 44, 372-380.
240. Thodtmann, R.; Depenbrock, H.; Dumez, H.; Blatter, J.; Johnson, R. D.; van Oosterom, A.; Hanauske, A. R. Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin. J. Clin. Oncol. 1999, 17, 3009-3016.
241. Adjei, A. A.; Erlichman, C.; Sloan, J. A.; Reid, J. M.; Pitot, H. C.; Goldberg, R. M.; Peethambaram, P.; Atherton, P.; Hanson, L. J.; Alberts, S. R.; Jett, J. Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors. J. Clin. Oncol. 2000, 18, 1748-1757.
242. Clarke, S. J.; Abratt, R.; Goedhals, L.; Boyer, M. J.; Millward, M. J.; Ackland, S. P. Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-naive patients with advanced non-small-cell lung cancer. Ann. Oncol. 2002, 13, 737-741.
243. Niyikiza, C.; Baker, S. D.; Seitz, D. E.; Walling, J. M.; Nelson, K.; Rusthoven, J. J.; Stabler, S. P.; Paoletti, P.; Calvert, A. H.; Allen, R. H. Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol. Cancer Ther. 2002, 1, 545-552.
244. Miles, D. W.; Smith, I. E.; Coleman, R. E.; Calvert, A. H.; Lind, M. J. A phase II study of pemetrexed disodium (LY231514) in patients with locally recurrent or metastatic breast cancer. Eur. J. Cancer 2001, 37, 1366-1371.
245. Vogelzang, N. J.; Rusthoven, J. J.; Symanowski, J.; Denham, C.; Kaukel, E.; Ruffie, P.; Gatzemeier, U.; Boyer, M.; Emri, S.; Manegold, C.; Niyikiza, C.; Paoletti, P. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 2003, 21, 2636-2644.
246. Smit, E. F.; Mattson, K.; von Pawel, J.; Manegold, C.; Clarke, S.; Postmus, P. E. ALIMTA (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: a phase II study. Ann. Oncol. 2003, 14, 455-460.
247. Hanna, N.; Shepherd, F. A.; Fossella, F. V.; Pereira, J. R.; De Marinis, F.; von Pawel, J.; Gatzemeier, U.; Tsao, T. C.; Pless, M.; Muller, T.; Lim, H. L.; Desch, C.; Szondy, K.; Gervais, R.; Shaharyar; Manegold, C.; Paul, S.; Paoletti, P.; Einhorn, L.; Bunn, P. A., Jr. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J. Clin. Oncol. 2004, 22, 1589-1597.
248. Rusthoven, J. J.; Eisenhauer, E.; Butts, C.; Gregg, R.; Dancey, J.; Fisher, B.; Iglesias, J. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 1999, 17, 1194-1194.
249. Manegold, C.; Gatzemeier, U.; von Pawel, J.; Pirker, R.; Malayeri, R.; Blatter, J.; Krejcy, K. Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multicenter phase II trial. Ann. Oncol. 2000, 11, 435-440.
250. Shepherd, F. A.; Dancey, J.; Arnold, A.; Neville, A.; Rusthoven, J.; Johnson, R. D.; Fisher, B.; Eisenhauer, E. Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group. Cancer 2001, 92, 595-600.
251. Scagliotti, G. V.; Kortsik, C.; Dark, G. G.; Price, A.; Manegold, C.; Rosell, R.; O'Brien, M.; Peterson, P. M.; Castellano, D.; Selvaggi, G.; Novello, S.; Blatter, J.; Kayitalire, L.; Crino, L.; Paz-Ares, L. Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial. Clin. Cancer Res. 2005, 11, 690-696.